Key result
Transcatheter PFO closure shows low recurrent stroke rates across long-term follow-up studies.
Why the study?
Although transcatheter PFO closure reduces recurrent ischemic stroke risk, residual shunting after device implantation is linked to significantly higher rates of recurrent stroke, motivating an evaluation of the incidence of fenestrated atrial septal defects in patients referred for PFO closure.
Observational
No
Answers are grounded in this paper and cite their sources.
May warrant closer post-PFO closure shunt surveillance; leaves open whether defect detection improves outcomes in prospective studies.
Randomized trials have documented that transcatheter patent foramen ovale (PFO) closure reduces recurrent ischemic stroke risk by preventing paradoxical embolism. In the landmark RESPECT trial at a median follow-up of 5.9 years, 3.6% of PFO closure patients had a recurrent ischemic stroke.1 In a population-based study, Danish investigators reported a 2.5% recurrent ischemic stroke rate 4 years following PFO closure.2 Residual shunting after device implantation is linked to significantly higher rates of recurrent stroke.
No takes yet. Share an insight, caveat, or question.
Kimmelstiel et al. (2026) conducted an observational in Patent foramen ovale and fenestrated atrial septal defects. Transcatheter patent foramen ovale closure referral was evaluated on Incidence of fenestrated atrial septal defects.
Synapse has enriched 10 related papers. Consider them for comparative context: